InvestorsObserver is giving Arbutus Biopharma Corp (ABUS) an Analyst Rating Rank of 70, meaning ABUS is ranked higher by analysts than 70% of stocks. The average projection by analysts for ABUS is $7 over the next 12 months and analyst’s classify the stock as a Strong Buy
Why are Analyst Ratings Important?
Though analyst projections should not be your only resource when determining your position on a stock, it can be a very useful tool. Analysts follow sectors/industries in-depth and tend to know how local and global conditions tend to affect demand and prices. Many analysts even participate in conference calls where they can get information to better make sense of the numbers.
InvestorsObserver averages the ratings provided by analysts and then ranks their score as a percent against the market. This allows you to compare stocks in a more comprehensive fashion than with the typical buy/sell/hold ranking.
What's Happening With Arbutus Biopharma Corp Stock Today?
Arbutus Biopharma Corp (ABUS) stock is trading at $4.06 as of 10:41 AM on Wednesday, Dec 23, a gain of $0.02, or 0.59% from the previous closing price of $4.04. The stock has traded between $3.86 and $4.08 so far today. Volume today is below average. So far 1,023,638 shares have traded compared to average volume of 4,748,047 shares.